SCHEMBL1869809

SCHEMBL1869809

CN(c1ccc([N+](=O)[O-])cc1)C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.64
CHRM3 P20309 1/20 0.64
ACHE P22303 7/20 0.59
BCHE P06276 4/20 0.59
BACE1 P56817 4/20 0.59
SIGMAR1 Q99720 2/20 0.56
MAPT P10636 2/20 0.52
ALDH1A1 P00352 2/20 0.52
LMNA P02545 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
RAB9A P51151 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21375648 0.84 SIGMAR1 (0.60) CHRM2CHRM3ACHESIGMAR1ALDH1A1
SCHEMBL21875703 0.82 KDM4E (0.62) CHRM2CHRM3ACHEBCHEBACE1
SCHEMBL13247558 0.79 ALDH1A1 (0.54) ACHESIGMAR1MAPTALDH1A1LMNA
SCHEMBL5626457 0.78 ALDH1A1 (0.74) ACHEBCHEBACE1SIGMAR1MAPT
SCHEMBL22314755 0.78 MAPT (0.50) ACHEMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL6153941 0.78 OPRM1 (0.68) CHRM2CHRM3SIGMAR1
SCHEMBL3156396 0.77 MEN1 (0.77) ACHEBCHEBACE1SIGMAR1MAPT
SCHEMBL3567508 0.77 KDM4E (0.56) CHRM2CHRM3ACHEBCHEBACE1
SCHEMBL6815072 0.77 SCN8A (0.56) CHRM2CHRM3ACHEBCHEBACE1
SCHEMBL3157355 0.76 DRD4 (0.65) CHRM2CHRM3ACHESIGMAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9108939-B2 (1, 1, 1,3,3,3-hexafluoro-2 hydroxypropan-2-yl) phenyl derivative, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME B.V. (NL) 2015-08-18 US disclosed
EP-2493855-B1 (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives, pharmaceutical compositions thereof and their use for the treatment of atherosclerosis MERCK SHARP & DOHME (NL) 2014-02-26 EP disclosed
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2012-09-20 US disclosed
EP-2493855-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS MSD Oss B.V. (NL) 2012-09-05 EP disclosed
WO-2011051282-A1 (1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238574-A1 (1, 1, 1,3,3,3 -HEXAFLUORO-2 HYDROXYPROPAN- 2 -YL) PHENYL DERIVATIVE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS TGFB1, FPR1, TGFB2 CHRM2 1645/4885CHRM3 1694/4885ACHE 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.